Inside Pfizer’s Vaccines Performance in 4Q17 and 2017
In 4Q17, Pfizer (PFE) generated revenues of $1.6 billion from the sale of vaccines, which reflected a ~8% rise on a YoY (year-over-year) basis.
Feb. 13 2018, Updated 3:35 p.m. ET
PFE’s vaccine revenue trends
In 4Q17, Pfizer (PFE) generated revenues of $1.6 billion from the sale of vaccines, which reflected a ~8% rise on a YoY (year-over-year) basis. In 4Q17, in the US and in international markets, vaccines generated revenues of $789 million and $828 million, respectively, compared with $846 million and $649 million in 4Q16.
In 4Q17, in international markets, Pfizer’s vaccines witnessed a 28% rise on a YoY basis. In emerging markets, Pfizer’s vaccines generated revenues of $403 million, which reflected a ~53% rise on a YoY basis in 4Q17.
In fiscal 2017, Pfizer’s vaccines generated revenues of $6.0 billion, which reflected a ~1% decline on a YoY basis. In 2017, in the US and in international markets, Pfizer’s vaccines generated revenues of $3.4 billion and $2.26 billion, respectively, compared with $3.6 billion and $2.1 billion in 2016.
Prevnar 13 revenue trends
In 4Q17, Pfizer’s Prevnar 13 reported revenues of $1.5 billion, which represents a ~8% rise on a YoY basis and a 1% rise quarter-over-quarter. In 4Q17, in the US and in international markets, Prevnar 13 reported revenues of $780 million and $753 million, respectively, compared with $835 million and $531 million in 4Q16.
In fiscal 2017, Prevnar reported revenues of $5.6 billion, which represents a ~2% fall on a YoY basis. In 2017, in the US and in international markets, Prevnar 13 reported revenues of $3.3 billion and $2.3 billion, respectively, compared with $3.6 billion and $2.1 billion in 2016.
FSME/IMMUN-TicoVac revenue trends
In 4Q17, Pfizer’s FSME/IMMUN-TicoVac vaccine reported revenues of $15 million, which reflected a ~22% rise on a YoY basis. In fiscal 2017, Pfizer’s FSME/IMMUN-TicoVac vaccine reported revenues of $134 million, compared with $114 million in 2016, reflecting an 18% rise on a YoY basis.
Notably, in 4Q17, vaccine peers GlaxoSmithKline (GSK), Merck (MRK), and Sanofi (SNY) reported revenues of $10.1 billion, $10.4 billion, and $10.2 billion, respectively.
In the next part of this series, we’ll check in with Pfizer’s position in the biosimilar market after 2017.